Carnival Cruise Line Just Says No to Marijuana Use On Board

posted in: | 0

Carnival Cruise Line Just Says No to Marijuana Use On Board | HWN

Carnival Cruise Lines wants you to know that you can not smoke marijuana on their cruise ships, or even bring it on board. Replying to a tweet Monday, the cruise line said “You cannot smoke Marijuana [sic] or bring it on board.” @ayeeyoo_cfo You cannot smoke Marijuana or bring it on board. — Carnival Cruise Line […]

Carnival Cruise Line Just Says No to Marijuana Use On Board | The Daily Chronic

The Daily Chronic

PuraMed BioScience Investigates the Integration of Hemp and THC-Free Cannabis Into Its Product Line

posted in: | 0

Schofield, WI (PRWEB) March 20, 2014

PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is aggressively investigating the development of cannabinoid and hemp-based products to add to its line of medicinal formulations.

PuraMed BioScience initially intends to manufacture THC-free formulations that create medicinal compounds that don’t produce the “high” associated with cannabis containing THC. Scientific research has shown that cannabinoids can be formulated to effectively treat conditions such as multiple sclerosis, Crohn’s disease, pain, neurodegenerative disorders, epilepsy, arthritis and combat the effects of cancer chemotherapy.

“Integrating cannabinoid-based medications into our product line makes sense with what we are already doing,” said Russell Mitchell, CEO of PuraMed BioScience. “Cannabis has been used medicinally for centuries. It has only been in the last 100 years that its schedule 1 drug status and the abuse of this product for non-medicinal purposes has detracted from its medicinal benefits. Just one look at PubMed and you will see over 400 medical articles that report that it provides a viable treatment to neurologic problems, inflammatory diseases, and pain.

“Due to recent changes in the legality and availability of cannabinoids, we believe the future looks extremely bright for the development of highly effective and safe treatments incorporating these hemp derived compounds,” said Mitchell.

Scientific evidence continues to grow as to the effectiveness and safety of certain cannabinoids used to treat a number of disease states. In his article, ‘I am doubling down’ on medical marijuana, published on CNN Health, Dr. Sanjay Gupta, practicing neurosurgeon and CNN Chief Medical Correspondent, confirms his previous article apologizing for dismissing the plant’s potential.

Dr. Gupta has seen first-hand the benefit of this substance in the lives of people as shown in his documentaries Weed and Weed2, which recently aired on CNN. During his documentaries, Dr. Gupta stated that, unlike some prescription pain relievers, no one has died from an overdose of cannabis.

Even the United States government holds patents on cannabis-based formulations.

PuraMed BioScience has been investigating this market for nearly two years and found that cannabinoids offer a structure and function that fits ideally with several of its existing technologies. “We have been following the studies that currently are being conducted in Israel,” said Mitchell.

The company has researched the potential efficacy of cannabinoid-based pain treatment for patients with rheumatoid arthritis and chronic back pain and found that there was evidence of a high probability of success. PuraMed believes that a combination of cannabinoids with other natural compounds can provide superior results while avoiding the often severe side effects of many of the prescription treatments.

“The results of our preliminary research combined with the fact that the US cannabis market is expected to grow to over $ 10 billion by 2018, are strong reasons to aggressively develop a cannabis and hemp-based product line,” said Mitchell. “Development of these products will continue our mission of providing safe, effective products that use natural ingredients.

“We are particularly interested in the development of a formulation that will help veterans who are suffering the effects of Post Traumatic Stress Disorder (PTSD),” said Mitchell. “An effective PTSD formulation in addition to our LipiGesic® M migraine product would allow us to provide veterans with two effective medications to relieve these debilitating conditions.”

According to reports, on March 14, 2014, Suzanne Sisley, a lead researcher at the University of Arizona received approval from the Public Health Service, a branch of the US Department of Health & Human Services to research medical marijuana’s effectiveness in the treatment of PTSD. This was the second of three approvals necessary to conduct the research. The research has been approved by the US Food and Drug Administration (FDA) and is awaiting approval from the Drug Enforcement Administration (DEA).

At this point in time, six states approve the use of medical cannabis for PTSD.

PuraMed BioScience intends to become a leader in the cannabinoid-based medicine market utilizing its proven ability to develop and produce highly effective plant based medicines. The company has historically used scientific and clinical studies to prove the efficacy and safety of its products. PMBS expects to lead the way in conducting the same level of validated science for any product that contains cannabinoids.

“We’ve produced a highly effective acute migraine medication using feverfew and ginger that has been clinically tested and found to provide efficacies that perform better than its prescription counterparts,” said Mitchell. “We have faced an uphill battle with the adoption of homeopathic drugs in the mainstream, but we see that changing as well.”

In the March 24, 2014 issue of Woman’s World, LipiGesic® M is featured in an article entitled, “No more migraine pain!” The combination of feverfew and ginger was a treatment for migraine was also mentioned in “Nature’s First Aid Kit” which appeared in the February 2014 issue of O The Oprah Magazine.

“Publication in these magazines proves that the public is beginning to embrace the idea of “natural and safe” medications made with homeopathic formulations,” said Mitchell. “As more of the public embraces natural medicinal products, we will continue to provide formulations that operate with the highest level of efficacy and safety, which will allow people to choose a natural alternative without compromising treatment outcomes.”

About LipiGesic M:

Results of a double-blind, placebo-controlled clinical trial for LipiGesic®M show LipiGesic M is a highly effective treatment for acute migraine. The study was published in the July 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain. In addition to LipiGesic M, the Company also has plans to launch LipiGesic® H, tension headache remedy, as well as LipiGesic® PM, a remedy for insomnia and other sleep disorders.

Forward-Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:

PuraMed BioScience, Inc.

Russell Mitchell, Chairman and CEO

715-359-6373

rmitchell(at)PuramedBioScience(dot)com

http://www.PuramedBioScience.com







PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line

posted in: | 0

Schofield, WI (PRWEB) March 24, 2014

PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

PuraMed BioScience initially intends to develop and manufacture hemp and THC-free formulations that create medicinal compounds that don’t produce the “high” associated with cannabis containing THC. Scientific research has shown that cannabinoids can be formulated to effectively treat conditions such as multiple sclerosis, Crohn’s disease, pain, neurodegenerative disorders, epilepsy, arthritis and combat the effects of cancer chemotherapy.

“Integrating cannabinoid-based medications into our product line makes sense with what we are already doing,” said Russell Mitchell, CEO of PuraMed BioScience. “Cannabis has been used medicinally for centuries. It has only been in the last 100 years that its schedule 1 drug status and the abuse of this product for non-medicinal purposes has detracted from its medicinal benefits. Medical journal publication sites list many medical articles that report cannabinoids provide a viable treatment to neurologic problems, inflammatory diseases, and pain.

“Due to recent changes in the legality and availability of cannabinoids, we believe the future looks extremely bright for the development of highly effective and safe treatments incorporating these hemp derived compounds,” said Mitchell.

Scientific evidence continues to grow as to the effectiveness and safety of certain cannabinoids used to treat a number of disease states. In his article, ‘I am doubling down’ on medical marijuana, published on CNN Health, Dr. Sanjay Gupta, practicing neurosurgeon and CNN Chief Medical Correspondent, confirms his previous article apologizing for dismissing the plant’s potential.

Dr. Gupta has seen first-hand the benefit of this substance in the lives of people as shown in his documentaries Weed and Weed2, which recently aired on CNN. During his documentaries, Dr. Gupta stated that, unlike some prescription pain relievers, no one has died from an overdose of cannabis.

Even the United States government holds patents on cannabis-based formulations.

PuraMed BioScience has been investigating this market for nearly two years and found that cannabinoids offer a structure and function that fits ideally with several of its existing technologies. “We have been following the studies that currently are being conducted in Israel,” said Mitchell.

The company has researched the potential efficacy of cannabinoid-based pain treatment for patients with rheumatoid arthritis and chronic back pain and found that there was evidence of a high probability of success. PuraMed believes that a combination of cannabinoids with other natural compounds can provide superior results while avoiding the often severe side effects of many of the prescription treatments.

“The results of our preliminary research combined with the fact that the US cannabis market is expected to grow to over $ 10 billion by 2018, are strong reasons to aggressively develop a cannabis and hemp-based product line,” said Mitchell. “Development of these products will continue our mission of providing safe, effective products that use natural ingredients.

“We are particularly interested in the development of a formulation that will help veterans who are suffering the effects of Post Traumatic Stress Disorder (PTSD),” said Mitchell. “An effective PTSD formulation in addition to our LipiGesic® M migraine product would allow us to provide veterans with two effective medications to relieve these debilitating conditions.”

According to reports, on March 14, 2014, Suzanne Sisley, a lead researcher at the University of Arizona received approval from the Public Health Service, a branch of the US Department of Health & Human Services to research medical marijuana’s effectiveness in the treatment of PTSD. This was the second of three approvals necessary to conduct the research. The research has been approved by the US Food and Drug Administration (FDA) and is awaiting approval from the Drug Enforcement Administration (DEA).

At this point in time, six states approve the use of medical cannabis for PTSD.

PuraMed BioScience intends to become a leader in the cannabinoid-based medicine market utilizing its proven ability to develop and produce highly effective plant based medicines. The company has historically used scientific and clinical studies to prove the efficacy and safety of its products. PMBS expects to lead the way in conducting the same level of validated science for any product that contains cannabinoids.

“We’ve produced a highly effective acute migraine medication using feverfew and ginger that has been clinically tested and found to provide efficacies that perform better than its prescription counterparts,” said Mitchell. “We have faced an uphill battle with the adoption of homeopathic drugs in the mainstream, but we see that changing as well.”

In the March 24, 2014 issue of Woman’s World, LipiGesic® M is featured in an article entitled, “No more migraine pain!” The combination of feverfew and ginger was a treatment for migraine was also mentioned in “Nature’s First Aid Kit” which appeared in the February 2014 issue of O The Oprah Magazine.

“Publication in these magazines proves that the public is beginning to embrace the idea of “natural and safe” medications made with homeopathic formulations,” said Mitchell. “As more of the public embraces natural medicinal products, we will continue to provide formulations that operate with the highest level of efficacy and safety, which will allow people to choose a natural alternative without compromising treatment outcomes.”

About LipiGesic M:

Results of a double-blind, placebo-controlled clinical trial for LipiGesic®M show LipiGesic M is a highly effective treatment for acute migraine. The study was published in the July 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain. In addition to LipiGesic M, the Company also has plans to launch LipiGesic® H, tension headache remedy, as well as LipiGesic® PM, a remedy for insomnia and other sleep disorders.

Forward-Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:

PuraMed BioScience, Inc.

Russell Mitchell, Chairman and CEO

715-359-6373

rmitchell(at)PuramedBioScience(dot)com

http://www.PuramedBioScience.com







Naturally Splendid Rides Booming Heath & Wellness Wave With Plant-based Superfood Product Line

posted in: | 0

Burnaby, BC (PRWEB) December 17, 2013

From his office in Vancouver, BC, Craig Goodwin looks south to the world’s largest market for omega-3 health food supplements; it’s an alluring prospect.

The phenomenon is certainly worldwide. In 2012 the global market for omega-3 products was valued at US$ 33 billion and was the third fastest-growing supplement globally between 2007 and 2012 with a 12% annual growth rate. In Canada alone, there has been a 1,766 per cent growth in consumption of omega-3 natural health products since 2005, according to Ipsos-Reid.

Booming interest in omega-3 supplements stems mainly from heart, brain, and vision benefits and the industry shows no sign of slowing down as consumers are constantly becoming more astute and aware of the food they eat.

Goodwin and his long-time friend and business partner Bryan Carson were among the first to spot “this massive opportunity” more than six years ago. They formed a publically traded company, Naturally Splendid Enterprises (TSX-V: NSP), to market a line of plant based omega-3 rich superfoods now called NATERA™. (http://www.naturallysplendid.com) (http://www.nateralife.com)

Currently, the most common source of omega-3 is derived from fish and it’s now common knowledge that the World’s oceans and rivers are becoming increasingly contaminated with toxic pollutants which can build up in fatty fish tissue. The pollutants can cancel out the beneficial effects of the omega-3s they contain and can be harmful to children, adults and unborn babies. Farmed fish unfortunately do not offer an answer; they contain less omega-3s than their wild counterparts and even more toxins.

The good news is you don’t have to eat fish or the neurotoxins and carcinogens they contain to get your omega-3s; there are perfectly pure plant sources, enter Naturally Splendid.

Recent studies show that omega-3s from plants can offer all of the benefits of fish based omega-3 without exposing you to harmful toxins. Plant-based omega-3s provide better protection from heart disease and many other degenerative conditions. A 2013 report published by Amadee & Company Inc. states, “Plant based omega 3 production value is expected to grow twice as fast as marine during the next five years. As a result, by 2018, plant based omega-3s will account for 52% of production value compared to 48% for marine. Plant based omega-3s will benefit from consumers’ desire to get away from animal based products.”

This benefits the environment as well; plant-based sources of omega-3s are sustainable, fish are not. The environmental argument for switching to plant-based omega-3s cannot be ignored. Commercial fishing is devastating the world’s oceans and fish stocks are plummeting. Flax, Hemp, Chia and other plant-based sources of omega-3s are sustainable sources of this important fatty acid as well as being the healthier option. The many arguments supporting the move towards plant-based omega-3s away from fish oils are indisputable.

Naturally Splendid’s current transition from regional retailer to a potential global player in the health supplement industry has been made possible through an exclusive agreement with a company called Boreal Technologies Inc; a private company engaged in scientific research of plant based omega fatty acids, whose laboratories are on the Vancouver campus of the University of British Columbia (UBC).

Goodwin explains, “Boreal has developed the science that allows plant-based omegas to be mixed into most dry goods or liquids. The omega enriched product possibilities are almost limitless; with applications in most anything you bake or drink.”

Naturally Splendid was introduced to Boreal early in 2012. Goodwin states “within five minutes of our meeting we realized that what Boreal was developing was a breakthrough application for plant-based omega oils. We have since learned that the science Boreal is developing far surpasses our first impression, and the science is transferable to a wide range of plant-based omega products.”

Boreal, a company at the forefront of research into industrial hemp has developed a range of revolutionary plant-based omega products, in powdered and aqueous forms, using micro-encapsulation and liposomal technology. In plain terms, the technology enables plant-based omegas to be used in a huge range of food products, with an extended shelf life. The “delivery system” developed by Boreal also allows for the optimum absorption by the human body of the essential fatty acids (EFAs) in omega products.

Boreal was looking for someone to market its patent-pending products, and Naturally Splendid was a natural fit. A relationship built up over eighteen months resulted, at first, in an agreement giving Naturally Splendid marketing rights in Canada. Then, in November 2013, the company won exclusive rights to market and distribute the full range of Boreal’s plant-based omega products right across North America.

The initial products developed by Boreal; HempOmega™ and H2Omega™ are based on hemp oil. Boreal has taken the technology developed for hemp products and adapted it to also produce FlaxOmega™, CanolaOmega™ and ChiaOmega™ — created respectively from flax, canola and chia incorporating the same micro-encapsulation and liposomal technologies.

Boreal’s agreement with Naturally Splendid has already borne fruit. The company’s shares jumped after Naturally Splendid signed a non-disclosure agreement with North American food ingredient supplier Caldic in early November. Ontario-based Caldic has been a global player in the ingredient supply business since 1985. Under the deal, Caldic is testing the suitability of Naturally Splendid’s line of omega products as potential offerings to its global clients as a premix for a wide variety of consumer foods.  In September, Naturally Splendid had signed a similar agreement with another independent ingredient supplier, Calico Food Ingredients, of Kingston Ont. “This is the first step to commercialization of these proprietary products, with the potential to generate large volume sales,” ” says Goodwin.

Even as Naturally Splendid looks to capitalize on the global potential of these omega products, the company is aggressively growing domestic sales of its existing NATERA™ retail line. The company’s hemp-based products are currently available in stores Canada-wide and are taking new orders on almost a weekly basis.

Newly rebranded under the name NATERA™, the products includes shelled hemp seeds and four flavors of hemp protein powder. NATERA™ is also the first brand to market single serve flavored shelled hemp seeds. “We’ve spent four years doing market research, developing and refining our products and becoming experts in the superfoods industry,” says Goodwin.

The attention to detail has paid off. “The interest shown by national distributors of natural products in Canada has been impressive,” says the CEO. “We are in negotiations with several national distributors who want to take our product and market it coast to coast.”

The NATERA™ line is expected to produce a positive cash flow by the first quarter of 2014 and has the potential for gross sales of $ 5 million for the 2014 fiscal year. Goodwin admits: “The retail line may not sound as exciting as the omega technology side of our business, but it will allow us to run the company efficiently, without having to go repeatedly to the market to raise operating capital”.

Goodwin says that after a lifetime in sales and marketing, he expected initial skepticism when presenting the plant based omega superfood line. But “we knew we had something special on our hands when literally 100-per-cent of the people we contacted with these plant-based omega products, wanted samples for testing.”

Naturally Splendid has a balanced strategy that drives revenue from a growing retail product line and incorporates the exciting upside potential of a technology-driven company in a booming market. Goodwin summarizes, “We are offering the best of both worlds — a successful retail line in an explosive market category, and a technology-driven company utilizing ground-breaking science with the potential for global reach. Naturally Splendid delivers on both counts.”

Naturally Splendid currently trades on the TSX Venture under the symbol “NSP”.

http://www.naturallysplendid.com

Legal Disclaimer/Disclosure:

A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author’s only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.







Related Hemp Farming Press Releases